GlobalRPh Renal Dosing Masterv6.6
Source review / handoff

Naloxegol tablets (Movantik, adults)

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Return to full drug recordAll source differencesRead selected sourcesHow to use this review

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

Naloxegol tablets (Movantik, adults) - selected U.S. label sections

Product / population
Adult MOVANTIK oral tablets for opioid-induced constipation.
Renal method
Creatinine clearance in mL/min
Source revision
Revision not captured; retrieval date is not the revision date.
Retrieved
2026-09-05
Local review status
Local label summary; independent clinical review pending. Not a two-source validated protocol.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

MOVANTIK: renal starting dose and conditional escalation

The higher dose is a conditional option after tolerance and inadequate response, not the default renal maintenance dose. CYP3A interactions can impose additional restrictions.

What to reconcile: Check the renal starting dose and interaction pathway before considering escalation.

Source-specific interpretation; independent clinician adjudication pending.

Open this note and its source references
Official

Naloxegol tablets (Movantik, adults) - selected U.S. label sections

Open original reference

U.S. product labeling / DailyMed · Adult MOVANTIK oral tablets for opioid-induced constipation.

Renal method: Creatinine clearance in mL/min
Source date: Revision not captured; retrieval date is not the revision date.
Retrieved: 2026-09-05

Local label summary; independent clinical review pending. Not a two-source validated protocol.

Renal starting dose and cautious escalation

For CrCl below 60 mL/min, including severe or end-stage impairment, start 12.5 mg once daily. If well tolerated but constipation persists, the label permits increasing to 25 mg once daily after considering increased exposure and adverse-reaction risk. Mild impairment does not require adjustment.

RDM32-naloxegol-movantik-1 · Source locator: 2.3; 8.6

Dialysis and other cautions

The renal starting recommendation is not replaced with a larger dose solely because the patient receives hemodialysis. Review the contraindications, CYP3A interactions and gastrointestinal warnings separately.

RDM32-naloxegol-movantik-2 · Source locator: 2.3; 4; 5; 7; 12.3

Source-specific limits

Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.

Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=300a6474-ebcd-4404-8040-48fdcfcc1635
Retrieved
2026-09-05
DailyMed Set ID
300a6474-ebcd-4404-8040-48fdcfcc1635
Renal-function method
Creatinine clearance in mL/min
Source date/version
Revision not captured; retrieval date is not the revision date.
Hash meaning
SHA-256 identifies this local summary, not original SPL XML or a label PDF.
Local summary SHA-256
eb10009fdf07e972254a1e962d929e616ccafbbcc7f96c3c7cb3e54316f7dd27

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=naloxegol-movantik&s1=RDM32-label-naloxegol-movantik&h1=63a001b0310f82a4af40ad7ac49a0ca37d7f26e5b9903e5979df4ff5d6748b74